Joachim Gullbo

Uppsala, C, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications

Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma.

Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma.

Journal: Journal of clinical pharmacology
Published: May 12, 2023

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes.

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes.

Journal: Bone reports
Published: April 22, 2021

Melflufen for relapsed and refractory multiple myeloma.

Melflufen for relapsed and refractory multiple myeloma.

Journal: Expert opinion on investigational drugs
Published: September 14, 2020

Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma.

Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma.

Journal: Journal of clinical medicine
Published: July 27, 2020

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.

Journal: Investigational new drugs
Published: February 12, 2020

Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide.

Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide.

Journal: Therapeutic advances in medical oncology
Published: January 21, 2020

Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15.

Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15.

Journal: PloS one
Published: June 19, 2019

A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation.

A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation.

Journal: Oncotarget
Published: February 18, 2019

Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.

Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.

Journal: Leukemia research
Published: July 16, 2017

Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.

Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.

Journal: BMC research notes
Published: December 28, 2016

Melflufen - a peptidase-potentiated alkylating agent in clinical trials.

Melflufen - a peptidase-potentiated alkylating agent in clinical trials.

Journal: Oncotarget
Published: October 09, 2016

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity.

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity.

Journal: Oncotarget
Published: September 07, 2016
Showing 1-12 of 48

Last Updated: 09/26/2026